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Improving palliative treatment of patients with non-
operable cancer of the oesophagus: training doctors and 
nurses in the use of self-expanding metal stents (SEMS) 
in Malawi
   Abstract
Cancer of the oesophagus is the 6th most common cancer in Malawi. 
Nationwide only three hospitals are able to perform oesophagectomies, 
and there is no radiotherapy- or chemotherapy available.  Owing to 
late presentation of the patients (sometimes in combination with co-
morbidities such as HIV/AIDS or tuberculosis) the vast majority of 
patients are not suitable for surgery.  Self-expanding metal stents (SEMS) 
of the oesophagus provide  a suitable palliative option to improve the 
quality of life for patients. This project took a nationwide approach, 
raising funds for both technical equipment and training of endoscopists 
and nursing staff throughout Malawi. 
Introduction
Cancer of  the oesophagus is the 9th most common cancer 
worldwide and the 5th most common cancer in developing 
countries with approximately 300 000 newly diagnosed 
patients every year1. In Africa there is a high incidence of  
oesophageal cancer in parts of  South Africa particularly 
in the Transkei districts and Central and Eastern Africa, 
especially in the central region of  Kenya, Central Zimbabwe 
and - of  special interest for our project – Malawi with an 
estimated incidence in Malawi of  0.6 per 100 000 per year2-
5. Patients often present with dysphagia, but owing to the 
elastic properties of  the oesophageal wall this is generally a 
sign of  an advanced disease. Given that the oesophagus has 
no serosal layer to contain the local spread of  the tumour, 
the cancer is locally advanced and inoperable in more than 
80% of  the patients at the time of  first diagnosis6 so that the 
outcome is poor, with a less than 10% overall 5-year-survival 
rate7. 
The treatment of  cancer of  the oesophagus includes radical 
surgical resection with oesophageal reconstruction. Results 
vary depending on the stage of  the disease. Combined 
therapies, with down-staging of  the tumour with neoadjuvant 
radio-chemotherapy followed by surgery, seem to be more 
successful8. There is significant morbidity associated with 
oesophageal resections9,10.  Palliative treatment modalities 
include  chemo-radiation, argon-laser therapy, cryotherapy 
or self-expanding metal stents11. Most of  these are not 
available in developing countries because of  resource and 
infrastructure constraints. In any case, recent advances in 
more aggressive radiochemotherapy for patients with late 
stage presentation have not provided much benefit12. Self-
expanding metal stents are an established palliative single 
treatment for patients with non-operable cancers of  the 
oesophagus13 in countries without availability of  radio-
chemotherapy.  Stents provide  fast, complete and life-long 
improvement of  the leading symptom – dysphagia – with a 
reasonably low rate of  early and late complications14. So far 
there has been only very limited experience with SEMS in 
Malawi. Reasons for this include lack of  reasonably priced 
stents, lack of  training in their utilization and poor resources 
available for palliative care follow up. The aim of  this project 
was to build up the capacity for a nation-wide treatment 
programme for patients with non-operable cancer of  the 
oesophagus in Malawi.
Map of Malawi with participating endoscopy centers
Methods
Training of doctors in placement of SEMS in Malawi:
The project was funded by  generous financial support 
from The Lions Club of  Blantyre, Press Trust Malawi 
and the Society of  International Humanitarian Surgeons. 
Hospitals throughout Malawi performing endoscopies 
were invited to the training programme. Two workshops 
were organized – in Blantyre (at Queen Elizabeth Central 
Hospital and Mwaiwathu Hospital ),  and in Lilongwe (at 
Kamuzu Central Hospital).  Professor Dr. Russell White, an 
international expert on the management of  advanced cancer 
of  the oesophagus (who has performed more than 1000 
stent procedures) from Tenwek Hospital, Kenya  was invited 
to train the endoscopists in Malawi. Running parallel to the 
surgical workshops were palliative care training seminars for 
nurses to support the programme in ongoing patient care. 
Stents, dilators, and guide wires were purchased from the 
project funds. 
The SEMS are placed without use of  an image intensifier 
during an endoscopy. The tumour stenosis is dilated after 
placing of  a guide wire, the tumour is passed to check the 
correct position of  the guide wire in the antrum, the size of  
the tumour is measured and the SEMS is introduced with an 
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applicator with a proximal and distal overlap of  about 2cm. 
After replacement of  the applicator the SEMS expands to a 
size of  approximately 18 mm.
Nurse training included modules on breaking bad news, 
counselling the patients about dietary advice after stent 
placement, and pain management. 
Table 1: Participating Endoscopy Units throughout Malawi
Results
During the workshop 18 doctors and 46 nurses from 11 
hospitals were trained. Professor Dr. White gave the audience 
an overview about cancer of  the oesophagus with special 
focus on south-eastern Africa. In a video-demonstration 
he familiarised the participants with the basic procedure of  
stenting. Possible early complications such as bleeding, pain 
and perforation and their management were discussed. Severe 
pain could be treated effectively with oral pain medication 
(e.g. liquid morphine) or diclofenac suppositories for mild-
moderate pain. Bleeding after the dilatation normally subsides 
spontaneously. In case of  a possible perforation (revealed by 
surgical emphysema or by clinical and radiological signs of  
a pneumothorax) the first step is to place the stent despite 
the complication – the covered part of  the stent will seal the 
perforation, and if  necessary a chest drain may be inserted. A 
patient with an oesophageal perforation should be kept ‘nil 
by mouth’ for two days, and a broad spectrum intravenous 
antibiotic such as ceftriaxone could be given. Professor 
White has successfully treated 95% of   perforations in this 
way, without the need for  operation. 
Prof. R. White demonstrating the technique of stenting to participants 
at Queen Elizabeth Central Hosptial/Blantyre.
Following the theoretical introduction,  participants 
performed the placement of  a SEMS, supervised by Professor 
White.  Both real patients (who had fully consented) and 
a training model  were used for the stent placements. At 
Mwaiwathu Hospital in Blantyre stents were inserted with 
the assistance of  an image intensifier. This is not available at 
the other institutions. 
Table 2: Trained doctors and treated patients during workshops.
The workshop at Blantyre was performed at Queen Elizabeth 
Central Hospital (QUECH) and at Mwaiwathu Private 
Hospital for doctors and nurses of  the southern region of  
Malawi. At QECH the theoretical background was taught. 
Afterwards placement of  stents took place at both hospitals. 
The participants were able to see how safe stent insertion 
was possible despite differences between the resources 
of  the two hospitals.  Nine patients were treated with ten 
stents (in one patient the tumour had to be treated with two 
stents owing to tumour size) without any complications. The 
second workshop took place at Kamuzu Central Hospital 
at Lilongwe for doctors and nurses from the central and 
northern regions of  Malawi. Again nine patients were 
treated, this time one of  the possible complications occurred 
– a perforation during dilatation, with a right pneumothorax 
which was treated adequately with a chest drain. In this way 
participants were able to learn about the assessment and 
management of  possible complications of  stent insertion. 
Discussion
In Malawi more than 90% of  the oesophageal cancers 
found are squamous cell tumours15 (personal data). Beside 
the known risk factors – alcohol (especially spirits or local 
brewed beer) and smoking16,17 – there is some evidence that 
the consumption of  maize is increasing the risk of  squamous 
cell cancer of  the oesophagus through contamination by 
aflatoxins (secreted from fungi that grow on stored grain) 
or even through a direct influence of  maize on the mucosal 
layer of  the oesophagus18.  Co-infections with HIV, Human 
Papilloma Virus, schistosomiasis, EBV and CMV may also 
play a role and are subject to further investigations19-23. 
Given the high frequency of  oesophageal cancer, it is vital to 
improve the diagnosis and treatment of  this disease.
The majority of  patients presenting with cancer of  the 
oesophagus in Malawi have inoperable disease at presentation. 
SEMS placement is a simple, effective  method that can 
improve quality of  life in this condition in resource limited 
settings. Adopting a nationwide approach required dedicated 
funds and logistical support but has enabled all endoscopy 
sites in Malawi to gain skills both in stent insertion and in 
adopting a palliative care approach to these patients and their 
families. Since the training,  more than 120 patients have 
been successfully treated with SEMS with very good results 
in terms of  improvement of  dysphagia, and with a  low rate 
of  complications. These data will be published at the end of  
the planned follow-up of  200 patients after 12 months.
Complications are rare – early complications include bleeding, 
chest pain and perforation, while late complications include 
stent dislocation, tumour overgrowth or oesophagitis – the 
latter especially with a stent crossing the gastro-oesophageal 
junction. During the workshop one perforation happened 
and was treated adequately with a stent insertion, chest 
drain and iv-antibiotics. In a study in Kenya more than 1000 
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stents were inserted with an overall rate of  perforations of  
approximately 3%24. Tumour overgrowth could occur in up 
to 20% of  patients24: in our ongoing study, four patients out 
of  more than 120 have had to be re-stented, but without any 
problem due to a blockage of  the stent.
This project is unique because for the first time this technique 
will be used throughout Malawi in different endoscopy 
centres. With a lot of  effort a nationwide approach was made 
possible to supply a whole country with a new technique. 
Early results have shown that the procedure is easy to learn 
for endoscopists and that it  is safe even in resource limited 
countries. The success of  this programme can be used also 
in other developing countries to improve the palliative care 
for patients with cancer of  the oesophagus.
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